Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

Current recommendations suggest treating elderly CLL patients with good physical status and low burden of comorbidities with chemoimmunotherapy, consisting of non-fludarabine-based regimens.

Although it is treatable, it’s not considered to be curable. In the early stages, CLL often doesn't require treatment immediately, as studies have shown that early treatment doesn’t increase ...

Pirtobrutinib was also the subject of the BRUIN CLL-321 trial for patients who relapsed after covalent BTK inhibitor treatment, which represents a group of patients with limited treatment options.

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

But when CLL crowds out the healthy cells in your bone marrow and you get symptoms, you may need treatment. That’s what happened to Larry Saltzman, MD, a retired family doctor in Sacramento ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs. This means a stem cell transplant is now a less common treatment for CLL. You have a transplant using donor cells ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.